Patents by Inventor Martin Haberey

Martin Haberey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110124680
    Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Application
    Filed: February 2, 2011
    Publication date: May 26, 2011
    Inventors: Rolf BOHLMANN, Martin Haberey, Andreas Huth, Stuart James Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp, Andreas Reichel
  • Publication number: 20110071165
    Abstract: Aza- and polyazanthranyl amides and their use as medicaments in the treatment of diseases caused by persistent angiogenesis are described, as well as the intermediates used in the preparation of the aza- and polyazanthranyl amides.
    Type: Application
    Filed: November 24, 2010
    Publication date: March 24, 2011
    Applicant: NOVARTIS AG
    Inventors: Dieter SEIDELMANN, Martin KRÜGER, Orlin PETROV, Andreas HUTH, Karl-Heinz THIERAUCH, Andreas MENRAD, Martin HABEREY
  • Patent number: 7906533
    Abstract: The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Grant
    Filed: November 1, 2005
    Date of Patent: March 15, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp
  • Patent number: 7902229
    Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: March 8, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp, Andreas Reichel
  • Patent number: 7615565
    Abstract: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: November 10, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Andreas Huth, Ludwig Zorn, Martin Kruger, Stuat Ince, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • Patent number: 7572794
    Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: August 11, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart James Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp
  • Patent number: 7517894
    Abstract: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: April 14, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Andreas Huth, Ludwig Zorn, Martin Krueger, Stuart Ince, Karl Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • Patent number: 7479491
    Abstract: The invention relates to substituted anthranylalkyl and -cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: January 20, 2009
    Assignee: Novartis AG
    Inventors: Dieter Seidelmann, Martin Krueger, Eckhard Ottow, Andreas Huth, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey
  • Patent number: 7459470
    Abstract: Substituted N-oxidanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in the case of psoriasis, Kaposi's sarcoma, restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: December 2, 2008
    Assignee: Schering AG
    Inventors: Alexander Ernst, Andreas Huth, Martin Krueger, Karl-Heniz Thierauch, Andreas Menrad, Martin Haberey
  • Patent number: 7429592
    Abstract: Substituted cyanoanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in the case of psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: September 30, 2008
    Assignee: Schering Aktienegesellschaft
    Inventors: Alexander Ernst, Andreas Huth, Martin Krueger, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey
  • Publication number: 20070135489
    Abstract: Novel VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are selected.
    Type: Application
    Filed: January 18, 2007
    Publication date: June 14, 2007
    Inventors: Andreas Huth, Martin Krueger, Ludwig Zorn, Stuart Ince, Rolf Bohlmann, Karl Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • Patent number: 7211680
    Abstract: Compounds of Formula I, wherein Y1, Y2, R1–R6, Q and Z are as defined herein, are vitamin D derivatives. These compounds are useful for, e.g., the treatment hyperprolifierative diseases of the skin, tumor diseases and precancerous stages, auto-immune diseases, rejection reactions in the case of autologous, allogenic or xenogenic transplants, AIDS, atopic skin conditions, secondary hyperparathyroidism, renal osteodystrophia, senile and postmenopausal osteoporosis, diabetes mellitus type II, degenerative diseases of the peripheral and central nervous system, hypercalcemias, granulomatous diseases, paraneoplastic hypercalcemias, hypercalcemias in hyperparathyroidism, hirsutism, ateriosclerosis, and/or inflammatory diseases.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: May 1, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: Andreas Steinmeyer, Gerald Kirsch, Guenter Neef, Katiea Schwarz, Ruth Thieroff-Ekerdt, Herbert Wiesinger, Martin Haberey, Marianne Fahnrich
  • Patent number: 7202260
    Abstract: Novel VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are selected.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: April 10, 2007
    Assignee: Schering AG
    Inventors: Andreas Huth, Martin Krueger, Ludwig Zorn, Stuart Ince, Rolf Bohlmann, Karl Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • Publication number: 20070015794
    Abstract: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.
    Type: Application
    Filed: September 22, 2006
    Publication date: January 18, 2007
    Inventors: Andreas Huth, Ludwig Zorn, Martin Kruger, Stuart Ince, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • Publication number: 20060287339
    Abstract: Aza- and polyazanthranyl amides and their use as medicaments in the treatment of diseases caused by persistent angiogenesis are described, as well as the intermediates used in the preparation of the aza- and polyazanthranyl amides.
    Type: Application
    Filed: August 25, 2006
    Publication date: December 21, 2006
    Inventors: Dieter Seidelmann, Martin Kruger, Orlin Petrov, Andreas Huth, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey
  • Patent number: 7148357
    Abstract: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: December 12, 2006
    Assignee: Schering AG
    Inventors: Andreas Huth, Ludwig Zorn, Martin Kruger, Stuat Ince, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • Publication number: 20060264425
    Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Application
    Filed: November 3, 2005
    Publication date: November 23, 2006
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp
  • Patent number: 7115758
    Abstract: The invention relates to vitamin D derivatives of general formula I, process for their production, intermediate products of the process as well as the use for the production of pharmaceutical agents.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: October 3, 2006
    Assignee: Schering AG
    Inventors: Andreas Steinmeyer, Katica Schwarz, Claudia Giesen, Martin Haberey, Marianne Fähnrich
  • Patent number: 7081468
    Abstract: Ortho-substituted anthranilic acid amides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: July 25, 2006
    Assignee: Schering AG
    Inventors: Martin Krueger, Andreas Huth, Orlin Petrov, Dieter Seidelmann, Karl-Heinz Thierauch, Martin Haberey, Andreas Menrad, Alexander Ernst
  • Publication number: 20060160861
    Abstract: The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Application
    Filed: November 1, 2005
    Publication date: July 20, 2006
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp